ACVRL1 and colorectal carcinoma: Finally, we uncovered that the β-catenin/TCF-1-KCNQ1OT1-miR-7-5p axis participates in the activation of ACVRL1, blocking which may be a potential strategy for reversing mTKI resistance in CRC.